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Abstract
Background and Objective Cysteamine is licensed for use
in nephropathic cystinosis but preclinical data suggest a
role in managing cystic fibrosis (CF). This study aimed to
determine whether oral cysteamine is absorbed in adult CF
patients and enters the bronchial secretions. Tolerability
outcomes were also explored.
Methods Patients C18 years of age, weighing[50 kg with
stable CF lung disease were commenced on oral cys-
teamine bitartrate (Cystagon) 450 mg once daily,
increased weekly to 450 mg four times daily. Serial plasma
cysteamine concentrations were measured for 24 h after
the first dose. Participants were reviewed every week for
6 weeks, except at 4 weeks. Plasma cysteamine
concentrations were measured 8 h after dosing when
reviewed at 1, 2 and 3 weeks and 6 h after dosing when
reviewed at 5 weeks. Sputum cysteamine concentration
was also quantified at the 5-week assessment.
Results Seven of the ten participants reported adverse
reactions typical of cysteamine, two participants discon-
tinued intervention. Following the first 450-mg dose, mean
(SD) maximum concentration (Cmax) was 2.86 (1.96) mg/l,
the time corresponding to Cmax (Tmax) was 1.2 (0.7) h, the
half-life (t) was 3.7 (1.7) h, clearance (CL/F) 89.9 (30.5)
L/h and volume of distribution (Vd/F) 427 (129) L. Cys-
teamine appeared to accumulate in sputum with a median
(interquartile range) sputum:plasma cysteamine concen-
tration ratio of 4.2 (0.98–8.84).
Conclusion Oral cysteamine is absorbed and enters the
bronchial secretions in patients with CF. Although adverse
reactions were common, the majority of patients continued
with cysteamine. Further trials are required to establish the
risk benefit ratio of cysteamine therapy in CF.
Key Points
Oral cysteamine is absorbed after taken by adult
patients with cystic fibrosis and accumulates in the
bronchial secretions.
The pharmacokinetics of cysteamine in people with
cystic fibrosis are similar to those reported for people
with cystinosis.
Although seven of the ten patients experienced side
effects typical of cysteamine and led to the
withdrawal of one of the participants, the majority of
participants continued taking cysteamine.
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1 Introduction
Cystic fibrosis (CF) is an autosomal recessively inherited
multi-organ disease that affects 70,000–100,000 people
globally [1]. Most CF morbidity and mortality results from
chronic suppurative lung disease [2]. Many of the bacteria
infecting the lungs in CF are frequently resistant to
antibiotics [3] and grow in biofilms, further reducing
antibiotic sensitivity [4]. These issues have led to calls for
new antibiotic strategies targeting the biofilm and to
increase the effectiveness of currently available antibiotics
[5, 6].
We have previously described the in vitro antimicrobial,
anti-biofilm and mucoactive properties of the aminothiol
cysteamine as a monotherapy and synergy with CF
guideline recommended antibiotics [7–9]. Overall these
characteristics suggest that cysteamine could be beneficial
in managing CF and warrants further investigation.
Although cysteamine has been used to treat nephropathic
cystinosis for several decades [7] and its pharmacokinetic
and clinical profiles are established for cystinosis [7, 10–
12], there are no such data for cysteamine in CF. In patients
with cystinosis, absorption of oral cysteamine may be
decreased when taken with food [13], there is a 40 % first-
pass effect, cysteamine circulates bound to plasma pro-
teins, and is metabolised to taurine and excreted in the
urine and bile; cysteamine is also excreted in the urine as
inorganic sulphate and taurine [7, 14]. Given the pancreatic
and intestinal manifestations of CF and the increased drug
metabolism/clearance reported [15] in CF it is not possible
to extrapolate the pharmacokinetics of cysteamine in
cystinosis to CF. Critically it is not known in CF whether
orally administered cysteamine enters infected airways.
We report here a single-arm, phase 1/2a open label study
conducted to confirm in people with CF that oral cys-
teamine is absorbed, to characterise the pharmacokinetic
profile of cysteamine, to ascertain whether cysteamine
enters bronchial secretions and to explore tolerability.
2 Method
This was a single-centre, single-group, open-lable trial of
administering oral cysteamine to patients with CF. Figure 1
depicts the study design.
2.1 Participants
Patients attending the adult CF clinic at Aberdeen Royal
Infirmary, Aberdeen, UK were invited to participate. The
inclusion criteria were: CF lung disease, aged C18 years,
weight[50 kg, clinically stable for[4 weeks, and females
of child-bearing potential using a reliable form of contra-
ception. The exclusion criteria were: hypersensitivity to
cysteamine, excipients or penicillamine, transplant recipi-
ent, pregnancy, planned pregnancy, and breast feeding. The
trial was co-sponsored by the University of Aberdeen and
NHS Grampian, approved by Scotland-A Research Ethics
Committee (14/SS/056), the Medicines and Healthcare
products Regulatory Agency (EudraCT 2014-000284-40,
CTA 21583/0220/001-0001) and registered with http://
www.clinicaltrials.gov (NCT02212431). Participants pro-
vided written informed consent.
2.2 Intervention
Oral cysteamine bitartrate (Cystagon, Orphan Europe,
Henley-upon-Thames, UK) was administered at the dose
licensed for cystinosis, i.e. 450 mg four times a day (qds).
Participants were commenced on 450 mg once a day, with
the dose being increased at weekly intervals to 450 mg
twice daily (bd), 450 mg three times a day (tds) and
450 mg, which was administered for 2 weeks (Fig. 1). As
recommended, participants took cysteamine just after/with
food [16].
2.3 Follow-Up and Data Collection
Participants were assessed at face-to-face visits at recruit-
ment/baseline, and 1, 2, 3, 5 and 6 weeks (Fig. 1). The
recruitment/baseline assessment was conducted in an in-
patient facility, all other assessments were conducted in an
out-patient facility. At each assessment, blood was
obtained for routine clinical haematology and biochem-
istry. Adverse reactions (ARs) and serious adverse events
(SAEs) were ascertained at the 1-, 2-, 3-, 5- and 6-week
visits [17].
2.3.1 Plasma and Sputum Samples
At recruitment/assessment blood samples were taken prior
to and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 h after the
first 450-mg cysteamine dose that was administered by a
CF nurse specialist. Blood (5 ml) was collected into chilled
sodium heparin tubes, stored on ice until centrifuged at
2000g, 4 C for 10 min, and the plasma stored at -70 C
within 1 h of collection. Further blood samples were taken
3 h after the last dose of cysteamine at the 1-, 2-, 3- and
5-week visits. After a planned review of the pharmacoki-
netic metrics of the first four participants, the 24-h sample
after the first dose was made optional because plasma
cysteamine was below the lower level of quantification. In
addition, the timing of the blood sampling was changed to
8 h after last dosing for the 1-, 2- and 3-week assessments
and after 6 h for the 5-week assessment. These revisions
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were agreed by the Trial Steering Committee. A sponta-
neously expectorated sample of sputum (*1 ml) was
collected at the 5-week assessment immediately prior to
blood sampling and stored at -70 C within an hour of
collection.
2.3.2 Quantification of Cysteamine
Plasma and sputum cysteamine was quantified using pro-
tein precipitation and derivatisation followed by liquid
chromatography with tandem mass spectrometric detection
(LC-MS/MS) [18–20] by Covance Laboratories Ltd, Har-
rogate, UK. The validated method has a calibration range
of 0.020–5.000 mg/l. The analytical work was conducted
in accordance with: UK Statutory Instrument 2004 No.
1031: The Medicines for Human Clinical Use (Clinical
Trials) Regulations 2004, Statutory Instrument 2004
No.994 and Guidelines on Good Clinical Practice: ICH E6:
Good Clinical Practice CPMP/ICH/135/95 (July 1996).
2.3.3 Statistical Considerations
Primary outcomes were single-dose pharmacokinetic
parameters. Secondary outcomes were sputum cysteamine
concentration and tolerability. With 12 subjects the study
had 80 % power with a = 0.05 to detect a C1 SD differ-
ence in the mean maximal plasma concentration (Cmax)
after first dose of cysteamine between cystinosis [10] and
CF patients.
Pharmacokinetic parameters were identified using stan-
dard non-compartmental analysis from the single-dose
cysteamine concentration against time profiles. Cmax was
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment/baseline visit 
Informed consent.  
Inclusion/exclusion criteria, weight, blood samples for haematology, biochemistry. 
 
Commenced on Cysteamine 450mg od 
Blood cysteamine baseline, 30mins, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, (and 24) hours 
 
1 week follow up visit: Blood cysteamine 3/8 hours post dosing.  
Blood samples for haematology, biochemistry. 
Adverse events/reacons.  
Dose increase of Cysteamine 450mg bd?
2 week follow up visit: Blood cysteamine 3/8 hours post dosing.  
Blood samples for haematology, biochemistry. 
Adverse events/reacons. ?
Dose increase of Cysteamine 450mg tds?
3 week follow up visit: Blood cysteamine 3/8 hours post dosing??
Blood samples for haematology, biochemistry. 
Adverse events/reacons. ?
Dose increase of Cysteamine 450mg qds?
5  week follow up visit: Blood samples for haematology, biochemistry. 
Adverse events/reacons. 
Sputum sample for cysteamine. 
Blood cysteamine 3/6 hours post dosing.  
Stop Cysteamine  ?
6  week follow up visit: Blood samples for haematology, biochemistry. 
Adverse events/reacons. ?
Fig. 1 Study schedule. od once
a day, bd twice a day, tds three
times a day, qds four times a
day
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the greatest measured level and Tmax was the time corre-
sponding to Cmax. The elimination rate constant (k) was
obtained by linear regression of the natural logarithm
cysteamine concentration against time from the terminal
portion of each profile (i.e. all concentrations after the peak
concentration) and the half-life (t) was the natural loga-
rithm of two divided by the elimination rate constant. The
area under the curve between time t = 0 and the last
sample (Cfin-the final concentration) was calculated using
the trapezoidal rule (AUC0–Cfin). The area under the curve
(AUC) was the AUC0–Cfin plus the residual area (the final
measured concentration divided by the elimination rate
constant). The residual area ranged from 4.1 to 13.4 % of
the AUC for all participants. Bioavailability (F) of cys-
teamine tablets was not calculated, hence clearance (CL)
and volume of distribution (Vd) are reported as the
respective parameters divided by F (CL/F and Vd/F,
respectively). CL/F was obtained by dividing the dose by
the AUC and then dividing this value by the elimination
rate constant provided Vd/F. SPSS, v23.0. (Armonk, NY,
USA) was used for data analyses.
3 Results
Of the 65 patients attending the CF clinic, 32 were eligible
and invited to participate. Ten people participated between
September 2014 and February 2015, 22 declined to par-
ticipate. Two participants discontinued the intervention.
Figure 2 outlines flow through the trial. The clinical
characteristics of the participants are presented in Table 1.
3.1 Plasma Cysteamine
Serial plasma cysteamine concentrations after the first
450-mg cysteamine dose were quantified in nine partici-
pants, venous access issues prevented measurement in one
participant. A median (interquartile range, IQR) of 9
(7–10) time points were used to calculate half-life. Plasma
cysteamine concentrations and derived pharmacokinetic
parameters are presented in Fig. 3 and Table 2. Following
450-mg once a day (n = 8), twice a day (n = 9), three
times a day (n = 8) and four times a day (n = 8) dosing
the mean (SD) plasma cysteamine concentrations were
0.47 (0.26), 0.60 (0.34), 0.85 (0.73) and 0.47 (0.34) mg/l,
respectively. Four of the eight patients with measured
concentrations on four times a day dosing had lower con-
centrations than three times a day dosing although their pill
counts suggested good adherence.
3.2 Sputum Cysteamine
Six participants were able to expectorate sputum samples
immediately before blood sampling at the 5-week assess-
ment. Cysteamine was detected in all of these six sputum
samples, median (IQR) sputum cysteamine concentration
was 0.84 (0.41–2.10) mg/l. The median (IQR) ratio of
sputum to plasma cysteamine concentration was 4.2
(0.98–8.84).
3.3 Tolerability
Adherence as determined by pill counting appeared to be
good, with median (IQR) adherence for the once, twice,
three times and four times daily dosing being 100 %
(100–100), 100 % (93–100), 98 % (95–100) and 98 %
(79–100), respectively.
Twoparticipants discontinued the intervention: oneduring
the first week because of halitosis (an adverse reaction [AR]
related to cysteamine); the second duringweek three because
of recurrence of haemoptysis that continued after ceasing
medication (an AR unrelated to cysteamine). There were two
SAEs: one participant was hospitalised twice with infective
exacerbations of CF lung disease. These SAEs were deemed
unrelated to cysteamine. There were no deaths. Gastroin-
testinal ARs (anorexia, nausea, vomiting) were reported by
four participants, for three thiswas either short lived (2 days),
very mild or resolved with an increased dose of proton pump
inhibitor; for one participant symptoms persisted throughout
the trial. Neurological ARs (lethargy, somnolence, forget-
fulness) were reported by three participants. One participant
reported a transient rash after commencing cysteamine (a
possible AR). Seven participants reported at least one AR.
Two participants reported AEs judged unrelated to cys-
teamine. One participant reported no AE/ARs.
Assessed for eligibility (n=65) 
Excluded  (n=55) 
♦   Not meeting inclusion criteria (n=33) 
♦   Declined to participate (n=22) 
Lost to follow-up (n=0) 
Disconnued intervenon (halitosis, haemoptysis) (n=2) 
Allocated to intervention (n=10) 
♦ Received allocated intervention (n=10) 
♦ Did not receive allocated intervention (n=0) 
Analysed  (n=10) 
Enrolled (n=10) 
Fig. 2 CONSORT flow diagram
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Table 1 Baseline clinical
characteristics of participating
patients
Clinical characteristic Value
Age, years, median (interquartile range) 21.5 (19.8–31.8)
Female, n (%) 6 (60 %)
CF genotype: Phe 508del/Phe 508del, n (%) 8 (80 %)
CF genotype: Phe 508del/– 2 (20 %)
Body mass index, kg/m2, mean (95 % confidence interval) 22.1 (20.3–23.9)
Forced expiratory volume in first second (FEV1) % predicted, median (interquartile
range)
32 % (26–49)
Concomitant medication, n (%)
Pancreatic enzyme replacement 9 (90 %)
Azithromycin 8 (80 %)
Inhaled antibiotic 4 (40 %)
Nebulised recombinant DNAse 3 (30 %)
Nebulised 4 % saline 1 (10 %)
Ivacaftor 1 (10 %)
Sputum culture, n (%)
Staphylococcus aureus 3 (30 %)
Pseudomonas aeruginosa 6 (60 %)
Stenotrophomonas maltophilia 2 (20 %)
Fig. 3 Presentation of data on
mean (SD) plasma cysteamine
concentrations in the first 24 h
after an oral dose of 450 mg
(n = 9). Data points for t0–10 h
are mean (SD) of n = 9 and for
t = 24 h, mean (SD) of n = 7
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4 Discussion
We have shown that in adults with CF, oral cysteamine is
absorbed and enters the bronchial secretions with a higher
concentration than plasma values. Although ARs were
common, most participants continued the intervention.
Most of the plasma pharmacokinetic parameters repor-
ted here in patients with CF are similar to those reported in
cystinosis [10–12]. In patients with cystinosis, Belldina
reported a two-compartment model with Cmax 2.7 mg/l and
Tmax 84 min [11], Langman reported Cmax 2.73 mg/l, Tmax
72 min and clearance 1.33 l/min [10]. In our CF patients
volume of distribution and t were greater than those
reported after similar single dosing in people with cysti-
nosis (Vd/F = 180 L, SD 112, t = 90 min, SD 23) [10],
suggesting that whilst cysteamine absorption is similar in
cystinosis and CF, distribution and elimination differ. The
volume of distribution of cysteamine in people with CF
exceeds extracellular fluid volume, being similar to that
reported for aminoglycosides in CF. For aminoglycosides
this has been attributed to the compromised nutritional
status of patients with CF [15]. The between-subject vari-
ability of pharmacokinetic parameters as evidenced by
greater standard deviation values we report in CF patients
is greater than that reported for cystinosis [10–12]. This
may be a consequence of cysteamine being taken with
food, a factor known to cause wide variation in cysteamine
Tmax and Cmax [13]. Given the importance of maintaining
nutritional status in CF, it was not considered appropriate
for subjects to fast. Consideration of the physical properties
of cysteamine (acid dissociation constant, pKa = 10.4,
partition coefficient, logP = 0.01) [21] predicts that cys-
teamine concentration in the acidic bronchial secretions of
CF (pH 6.0–6.9) [22] should be higher than in the systemic
circulation, which is consistent with our findings. A study
published whilst our study was being conducted reported
that oral cysteamine was absorbed by CF patients [23].
Although similar in size to our study (n = 10), this study
differed somewhat: participants were younger, had milder
lung disease, were all Phe508del homozygous and plasma
cysteamine was quantified at baseline, 2 and 6 h for nine
subjects and hourly for 6 h for one subject.
The side effects of cysteamine are well documented for
cystinosis and consistent with what we observed in our CF
patients, with seven participants (70 %) reporting ARs.
Gastrointestinal ARs were most common and probably
similar incidence to those reported for cystinosis. More
participants reported neurological ARs (lethargy, somno-
lence, forgetfulness) than would be expected from the
cystinosis data. Although pill counts indicated good adher-
ence, the lower plasma levels after qds dosing compared to
tds dosing suggested greater adherence with tds dosing.
Anecdotally, participants spontaneously volunteered that
they found qds dosing very difficult to incorporate into their
daily routine. It is possible that for the qds dosing some of the
capsules taken from the bottles were not taken. In patients
with cystinosis, adherence is also poor in up to 70–80 % of
patients because of qds dosing and side effects [24–26].
The strengths of the current study are that the pharma-
cokinetic characteristics of cysteamine were established by
serial measurements of plasma cysteamine after single
dosing. When compared with UK CF Registry data the
patients participating in the current study had a greater
predominance of Phe508del homozygotes, lower lung
function, but similar BMI, Pseudomonas infection and
treatment modalities [27]. Quantification of sputum cys-
teamine was a further strength. Although sufficient to
characterise pharmacokinetic parameters the small number
of participants is a weakness. Our aim was to recruit 12
patients; however, ten volunteered, but this was in line with
pre-study expectations given the small clinic size and the
intensive nature of the study.
5 Conclusion
In conclusion, we have shown that in people with CF, oral
cysteamine is absorbed and preferentially accumulates in
sputum. However, randomised controlled trials are required
to establish whether and under what circumstances cys-
teamine could be used in the management of CF.
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